PUBLISHER: DelveInsight | PRODUCT CODE: 1462307
PUBLISHER: DelveInsight | PRODUCT CODE: 1462307
"OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of the OPDIVO for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the OPDIVO for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OPDIVO market forecast analysis for ovarian cancer in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response. Targeted immunotherapy has now become the most promising approach for tumor patients. PD-1 expressed on activated T-cells can reverse immune suppression and release T-cell activation. Nivolumab is an already established drug and is currently approved in different indications and for different patient segments.
Currently, the drug is being developed in a Phase II (NCT02873962) clinical study evaluating the drug in relapsed epithelial ovarian cancer.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OPDIVO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of OPDIVO for ovarian cancer in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of OPDIVO for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.